For Healthcare Professionals

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

clipboard-pencil

About the study

This is a randomized, open-label, multi-center Phase III study to determine the efficacy and safety of durvalumab versus platinum-based SoC chemotherapy in the first-line treatment of advanced NSCLC in patients who are epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type and with PD-L1 high expression (PEARL)
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria


  1. Aged at least 18 years
  2. Documented evidence of Stage IV NSCLC
  3. No sensitizing EGFR mutation and ALK rearrangement
  4. PD-L1 high expression
  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

EXCLUSION CRITERIA

Exclusion Criteria:


  1. Prior chemotherapy or any other systemic therapy for advanced NSCLC
  2. Prior exposure to immune-mediated therapy, including, but not limited to, other anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), anti-programmed cell death1 (PD-1), anti-programmed cell death ligand 1 (PD-L1), or anti PD-L2 antibodies, excluding therapeutic anticancer vaccines
  3. Brain metastases or spinal cord compression unless the patient is stable and off steroids for at least 14 days prior to start of study treatment
  4. Mixed small-cell lung cancer and NSCLC histology, sarcomatoid variant
  5. Active or prior documented autoimmune or inflammatory disorders (e.g., colitis or Crohn's disease]

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.

Study’s details


Contition

Non Small Cell Lung Carcinoma NSCLC

Age (in years)

18 - 130

Phase

Phase 3

Participants needed

671

Est. Completion Date

Aug 20, 2026

Treatment type

Interventional


Sponsor

AstraZeneca

ClinicalTrials.gov identifier

NCT03003962

Study number

D419AC00002

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.